Compare · QTI vs SLNO
QTI vs SLNO
Side-by-side comparison of QT Imaging Holdings Inc. (QTI) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QTI and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 67.9x QTI ($40.7M).
- Over the past year, QTI is down 53.8% and SLNO is down 24.3% - SLNO leads by 29.5 points.
- QTI has hit the wire 6 times in the past 4 weeks while SLNO has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 0 for QTI).
- Company
- QT Imaging Holdings Inc.
- Soleno Therapeutics Inc.
- Price
- $2.76+2.79%
- $53.02+0.08%
- Market cap
- $40.7M
- $2.76B
- 1M return
- -1.08%
- +0.76%
- 1Y return
- -53.85%
- -24.33%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 6
- 0
- Recent ratings
- 0
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest QTI
- iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
- Chief Executive Officer Dinu Raluca was granted 484,221 shares, increasing direct ownership by 53% to 1,393,066 units (SEC Form 4)
- QT Imaging Holdings Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 4 filed by Director Taylor Ross
- QT Imaging Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- QT Imaging Issues Mid-Year 2026 CEO Letter to Shareholders
- SEC Form 10-Q filed by QT Imaging Holdings Inc.
- QT Imaging Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- QT Imaging Delivers Strong Second Quarter Growth While Building the Foundation for Commercial Scale
- Director Timm Bryan was granted 9,000 shares (SEC Form 4)
Latest SLNO
- Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)